Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Stomach Neoplasms 2Rectal Neoplasms 1Prostatic Neoplasms 1Osteoarthritis 1Glioma 1Colorectal Neoplasms 1Colonic Neoplasms 1Cancer Pain 1Brain Stem Neoplasms 1Brain Neoplasms 1Barrett Esophagus 1Advanced Non-small Cell Lung Cancer 1Adenomatous Polyposis Coli 1

Interventions

Docetaxel 292Prednisone 241enzalutamide 195Leuprolide 185Radiotherapy 179Abiraterone Acetate 170Magnetic Resonance Spectroscopy 163bicalutamide 141Goserelin 138Androgen Antagonists 121acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108Radiosurgery 108apalutamide 93abiraterone 83gallium 68 PSMA-11 81Specimen Handling 73darolutamide 67Surveys and Questionnaires 64Gonadotropin-Releasing Hormone 63Triptorelin Pamoate 58Radiation 57Biopsy 57Brachytherapy 54cabazitaxel 53Standard of Care 51Radiotherapy, Intensity-Modulated 51Zoledronic Acid 50pembrolizumab 49luprolide acetate gel depot 49Flutamide 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × rofecoxib × Clear all
NCT00060476 2017-05-09

Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)

Merck Sharp & Dohme LLC

Phase 3 Completed
15,000 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡